Explore more publications!

Press Releases

Valneva Reports Full Year 2025 Audited Consolidated Financial Results
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
St. Louis’ Todd Mosby and an All-Star Lineup Capture Missouri’s Soul on Powerful New Album: American Heartland
TGR Foundation Celebrates 20 Years of Impact Through Education at TGR Learning Lab in Anaheim
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom
SCOR: Combined Shareholders’ Meeting of Tuesday 28 April 2026 – Availability of Preparatory Documents
Hypersanté Hosts First Francophone Summit on Longevity and Biohacking in Paris
Boulevard Kitchen & Oyster Bar Joins Vancouver World Chef Exchange: Bangkok × Vancouver
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
GBSA connects Pangyo’s innovative companies with global media outlets through the 2025 Pangyo Global Media Meet-Up
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance -  Publication of Circular for Combined Annual General Meeting of  September 30, 2025
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Combined General Meeting of June 11, 2025
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
Hypersante Introduces the 2026 Longevity and Biohacking Summit in Paris
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
Combined General Meeting of June 13, 2025
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions